

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00474)

CLARIFICATION ANNOUNCEMENT

Reference is made to the joint announcement jointly published by Aceso Life Science Group Limited (the “**Company**”) and HTICI on 22 June 2022 in relation to the major transaction of the Company relating to the Bonds Purchase (the “**Announcement**”) and the announcement of the Company dated 14 July 2022 in relation to the delay in despatch of the Circular (the “**Delay Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement and the Delay Announcement.

The Company would like to clarify that the Company has applied to the Stock Exchange for the Waiver. The Stock Exchange has on 15 July 2022 granted the Waiver in writing to the Company on the condition that the Company will despatch the Circular to the shareholders of the Company on or before 24 August 2022.

By order of the board of directors of
Aceso Life Science Group Limited
Fok Chi Tak
Executive Director

Hong Kong, 15 July 2022

As at the date of this announcement, the board of directors of the Company comprises three executive directors, namely Mr. Xu Haiying, Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.